1688-0420
1688-0420
S1688-04202021000201401
10.29277/cardio.36.2.8
00
08
2021
00
08
2021
36
2
[
1999
281
14
14
1291-7
]
[
2019
14
1
1
23-32
]
[
O'Connor CM.Van Veldhuisen DJ.Hillege HL
2014
35
7
7
455-69
]
[
1998
352
837-53
]
[
2008
358
24
24
2560-72
]
[
2009
360
2
2
129-39
]
[
2010
376
9739
9739
419-30
]
[
2007
356
24
24
2457-71
]
[
2011
27
4
4
107-14
]
[
1994
269
16
16
12032-9
]
[
2016
10
3
3
271-8
]
[
2017
120
1Supl
1Supl
S59-67
]
[
2015
373
22
22
2117-28
]
[
2017
377
7
7
644-57
]
[
2019
380
24
24
2295-306
]
[
2019
380
4
4
347-57
]
[
2019
393
10166
10166
31-9
]
[
2020
9
]
[
2020
383
15
15
1425-35
]
[
]
[
2019
7
11
11
845-54
]
[
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction J
2019
381
21
21
1995-2008
]
[
2020
383
15
15
1413-24
]
[
2020
383
15
15
1436-46
]
[
Al'Aref SJ.Khan MS.Al-Hawwas M.Vallurupalli S.Mehta JL
2021
232
10-22
]
[
2017
136
3
3
249-59
]
[
2018
14
1
1
17-23
]
[
2020
52
9
9
1705-12
]
[
2018
20
3
3
479-87
]
[
2018
32
2
2
213-22
]
[
2020
17
10
10
641-55
]
[
2020
16
10
10
556-77
]
[
2020
17
12
12
761-72
]
[
2020
43
3
3
508-11
]
[
2020
34
3
3
419-36
]
[
2021
12
1
1
6-20
]
[
2019
21
10
10
130
]
[
2019
20
13
13
3289
]
[
2021
34
3
3
673-80
]
[
2018
19
2
2
51-63
]
[
2020
cvaa323
]
[
2013
113
5
5
603-16
]
[
2018
61
10
10
2098-107
]
[
2020
2
11
11
1183-5
]
[
2019
15
4
4
275-85
]
[
1997
96
7
7
2190-6
]
[
2019
73
15
15
1931-44
]
[
2021
77
3
3
243-55
]
[
2020
43
3
3
501-7
]
[
2019
140
6
6
443-5
]
[
2020
133-34:106779
]
[
2017
136
17
17
1643-58
]
[
2019
15
4
4
275-85
]
[
2018
71
11 Suppl
11 Suppl
A674
]
[
2019
21
6
6
1291-8
]
[
2020
76
9
9
1117-45
]
[
2021
9
1
1
46-52
]
[
2020
35
Supl1
Supl1
i48-55
]